Citation Information :
Pillai LV, Husainy SM, Ramchandani K. Diabetic ketoacidosis associated with atypical antipsychotic drug, clozapine treatment: Report of a case and review of literature. Indian J Crit Care Med 2006; 10 (3):193-196.
Atypical antipsychotic drugs are associated with metabolic disturbances like weight gain, type 2 diabetes hyperglycaemia and dyslipedemia, which can result in serious health risk in patients. Diabetic ketoacidosis resulting in serious metabolic acidosis, occurring in a schizophrenic patient on treatment with clozapine is being reported to draw attention this association. Frequent monitoring of the blood sugar and lipids is advised before and during therapy with atypical antipsychotic drugs.
Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatr 2001;62:30-8.
Krosnick A, Wilson MG. A retrospective chart review of the clinical effects of atypical antipsychotic drugs on glycemic control in institutionalized patients with schizophrenia and comorbid diabetes mellitus. Clin Ther 2005;27:320-6.
Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes. Diabetes Care 2003;26:1597-605.
Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19:1-93.
Bergman RN, Ader M. Atypical antipsychotics and glucose heomeostasis. J Clin Psychiatr 2005;66:504-14.
Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine associated diabetes. Am J Med 2001;111:716-23.
Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatr 2002;14:59-64.
Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004;26:1936-46.
Ananth J, Venkatesh R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71:244-54.
Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five- year naturalistic study. Am J Psychiatr 2000;157:975-81
Haggs S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatr 1998;59:294-9.
Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: Practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004;24:S1-6.
Koren W, Kresis Y, Duchowiczny K, Prince T, Sancovici S, Sidi Y, et al. Lactic acidosis and fatal myocardial infarction due to clozapine. Ann Pharmacother 1997;31:168-70.
